Aflibercept--a decoy VEGF receptor.

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Aflibercept is a recombinant fusion protein acting as a decoy receptor for VEGF-A, VEGF-B, and PlGF.
• Its antiangiogenic properties were hypothesized to be broadly effective in tumors reliant on angiogenesis.

Purpose of the Study:

• To evaluate the clinical efficacy of aflibercept in various cancer types.
• To understand the mechanism of action and identify predictive biomarkers for aflibercept.

Main Methods:

• Review of preclinical studies and later-phase clinical trials involving aflibercept.
• Analysis of aflibercept's current FDA indication and its limitations.

Main Results:

• Preclinical studies showed promise, but later-phase clinical trials demonstrated limited efficacy across most tumor types.
• The only current FDA-approved indication is for metastatic colorectal cancer in specific patient populations.

Conclusions:

• Aflibercept's broad efficacy is not supported by current clinical evidence.
• Further investigation into its mechanism and predictive biomarkers is crucial for optimizing its use and managing its toxicity and cost in cancer therapy.